Related Experiment Video
Updated: May 26, 2026
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Betulinic acid derivatives in melanoma therapy: pharmacological assessment in a preclinical approach
Elenilson Figueiredo da Silva1, Jessica Gotardi1, Artur Stramari de Vargas1
1Laboratory of Phytochemistry and Organic Synthesis, Department of Raw Material Production, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil.
Abstract:
Melanoma is the deadliest form of skin cancer owing to its metastatic potential. In this study, the anticancer effects of Betulinic Acid (BA) derivatives were evaluated in melanoma models. The in vitro cytotoxic effect on B16-F10 (melanoma), VERO (kidney of adult African green monkey), and Hep-2 (laryngeal tumour) cells was determined using the MTT assay. Flow cytometry analysis was used to evaluate non-adherent human lymphocytes. The in vivo assay was performed on B16-F10 tumour bearing C57BL/6 mice. The BA derivatives oxime (3) and amine (4) showed the most significant cytotoxicity against B16-F10 cells, with IC50 3.2 and 12.4 µM, respectively, without statistically significant effects on healthy cells, and cell death mechanism involving apoptosis. In vivo, these derivatives led to approximately 90% tumour regression at 1.5 mg/kg when compared to the control group. These findings indicate that BA derivatives exhibit higher chemotherapeutic potential in melanoma cells than unmodified BA does.
Insights
Betulinic Acid derivatives show potent anticancer effects against melanoma. These compounds induced significant tumor regression in vivo and apoptosis in melanoma cells, offering promising therapeutic potential.
Area of Science:
- Oncology
- Pharmacology
- Dermatology
Background:
- Melanoma is a deadly skin cancer with high metastatic potential.
- Betulinic Acid (BA) is a natural compound with known anticancer properties.
- Investigating novel BA derivatives for enhanced melanoma treatment is crucial.
Purpose of the Study:
- To evaluate the anticancer effects of Betulinic Acid (BA) derivatives in melanoma models.
- To determine the in vitro and in vivo efficacy of specific BA derivatives.
- To elucidate the mechanism of cell death induced by these derivatives.
Main Methods:
- In vitro cytotoxicity assessed using MTT assay on B16-F10, VERO, and Hep-2 cell lines.
- Flow cytometry used to analyze effects on human lymphocytes.
- In vivo efficacy tested on B16-F10 tumor-bearing C57BL/6 mice.
Main Results:
- BA derivatives oxime (3) and amine (4) exhibited significant cytotoxicity against B16-F10 melanoma cells (IC50: 3.2 and 12.4 µM).
- These derivatives demonstrated selective toxicity, sparing healthy VERO and Hep-2 cells.
- In vivo studies showed approximately 90% tumor regression at 1.5 mg/kg, indicating potent therapeutic activity.
- Apoptosis was identified as the primary mechanism of cell death.
Conclusions:
- BA derivatives, particularly oxime (3) and amine (4), possess superior chemotherapeutic potential compared to unmodified BA.
- These derivatives represent promising candidates for melanoma treatment.
- Further research into BA derivatives could lead to novel melanoma therapies.
